An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19
Medicine
[키워드] 1:1
Administered
adverse event
adverse events
age
angiotensin receptor blocker
angiotensin receptor inhibitors
ARBs
average
Bayesian
capillary leakage
Comorbidities
contributing to
control group
controls
Coronavirus disease 2019
COVID-19
COVID−19
cumulative
disease severity
Efficacy
Endpoint
enrolled
Enrollment
hospital discharge
Hospitalized
illness
IMPROVE
incidence
incidence rate
inclusion criteria
Inflammation
lAbel
losartan
Lungs
male
measure
open label
oral
outcome
participant
Patient
Poisson regression
post-hoc
randomized trial
renin-angiotensin system
respiratory
respiratory compromise
Respiratory failure
Safe
Safety
secondary
Sex
treating
treatment group
Trial
vital status
[DOI] 10.3389/fmed.2021.630209 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2021.630209 PMC 바로가기 [Article Type] Medicine